A clinical study to evaluate the effect of livance-c, an anti-viral ayurvedic formulation for the treatment of covid-19 patients

Avance Phytotherapies Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Freshly detected and confirmed positive (by means of RT-PCR) COVID-19 patients requiring admission.
•Patients on whom no other (specifically targeted to treat COVID-19) treatment has been initiated. (Patients on supportive care can be considered for inclusion).
•Patients who have consented (written informed consent) to be treated
•with the trial drug as the primary treatment.
•Patient is in the age group between 18-65years.
•Patient has persistent fever >=99.50 F and is currently maintained on
•antipyretics.
•Patient is unable to take a deep breath and/ or not able to hold for >= 20
•Patient has a history of cough since >= 3 days.
•Patient has a history of body aches or tiredness or unusual fatigue lately
•(>= 7 days).
•Patients ability in the investigators opinion to comply with the protocol
•procedures.

•Suspected patients with COVID19, but not confirmed by RT-PCR test.
•Confirmed positive Patient on whom already alternative medical treatment has been initiated.
•History of tuberculosis.
•History / evidence of allergy or hypersensitivity to Hydroxychloroquine sulfate or of herbal drugs or to any of the inactive ingredients of the formulation or to any other drug.

发起方

Avance Phytotherapies Pvt Ltd